gms | German Medical Science

63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

13. - 16. Juni 2012, Leipzig

Treatment of Cervical Myelopathy, Conservative versus surgical treatment of mild to moderate spondylotic cervical myelopathy: A protocol for a prospective, randomized, controlled, multicenter trial

Meeting Abstract

Suche in Medline nach

  • E. Shiban - Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München
  • J. Villard - Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München
  • F. Ringel - Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München
  • B. Meyer - Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS). Leipzig, 13.-16.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocFR.03.03

DOI: 10.3205/12dgnc189, URN: urn:nbn:de:0183-12dgnc1893

Veröffentlicht: 4. Juni 2012

© 2012 Shiban et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Spondylotic cervical myelopathy (SCM) is a degenerative disease of the cervical spine and the leading cause of myelopathy in pts. over the age of 50. Despite significant advances in the understanding of this disease, SCM remains a clinical diagnosis and its natural history remains unclear. Therefore, the treatment of SCM is still controversial, especially in patients with mild or moderate clinical disease without rapid progression of symptoms. Aim of the planned trial is to assess whether decompressive surgery is superior to conservative treatment in mild to moderate SCM.

Methods: The TIME study (Treatment of cervIcal MyElopathy) is meant to be a prospective randomized controlled multicenter study. The primary study endpoint is the difference in overall success rate defined as maintenance or improvement of neurological status, measured by the modified Japanese Orthopaedic Association (mJOA) between treatment groups at 2 years post recruitment, as well as no additional treatment. Other outcome evaluation scores, radiological and electrophysiological follow-ups will also be analysed for thorough comparison of treatments. The study duration includes 18 months of recruitment followed by 2 years follow-up. 240 patients will be allocated to the trial and 200 patients are needed for significant differences to be observed. The primary analysis will be conducted following the intention-to-treat (ITT) principle.

Results: The TIME study protocol has been finalized and as a next step potentially participating centers will be contacted. FPFV is planned for 06/2012, LPLV 06/2015.

Conclusions: SCM treatment is a daily challenge and strong evidence is lacking. In order to achieve high-level evidence for the optimal treatment of mild to moderate cervical myelopathy we invite all interested institutions to participate in TIME.